Ibrutinib drug is used in all except:
Bruton tyrosine kinase (BTK) is a validated target for B cell malignancies. BTK inhibitor ibrutinib was approved in: - Chronic lymphocytic leukaemia- Mantle cell lymphoma- Waldenstrom's macroglobulinemia NIB -drug ending with NIB are kinase inhibitor BRUT - Bruton's tyrosine kinase inhibitor
Mantle cell lymphoma
Chronic lymphocytic leukemia
Waldenstrom's macroglobulinemia
AML
Targeted Anticancer Drugs and Immunosuppressants